Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Clinical High Risk for Psychosis (CHR) Cohort

10 novembre 2026 aggiornato da: Jijun Wang

A Prospective Longitudinal Cohort Study of Individuals at Clinical High Risk for Psychosis

This study aims to establish a standardized, prospective longitudinal cohort of individuals at clinical high risk for psychosis (CHR) to improve early identification, risk prediction, and outcome assessment of psychotic disorders.

The study will recruit individuals at CHR and healthy controls at Shanghai Mental Health Center. Participants will undergo comprehensive assessments covering clinical symptoms, neurocognitive functioning, psychosocial functioning, and multimodal biological characteristics. Assessments will include standardized clinical interviews and rating scales, neurocognitive tests, natural language sampling, eye-tracking, retinal imaging, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), magnetic resonance imaging (MRI), and biological marker assessments, as applicable.

Individuals at CHR will be followed for up to 36 months, with assessments scheduled at baseline and at 2, 6, 12, 24, and 36 months. Healthy controls will undergo assessments at baseline and at 2 months.

The primary outcome is transition to psychosis during follow-up, determined using standardized clinical criteria. Secondary outcomes include changes in clinical symptoms, psychosocial functioning, cognitive performance, and multimodal biological measures.

By integrating longitudinal clinical and multimodal data, this study seeks to identify risk factors and biomarkers associated with psychosis onset and clinical outcomes, and to develop predictive models that may support earlier identification and personalized preventive strategies.

This is an observational study, and no experimental interventions will be assigned as part of the study protocol.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

The study will collect comprehensive clinical, behavioral, neurocognitive, neurophysiological, neuroimaging, ophthalmic, linguistic, and biological data across the following domains:

  1. Clinical symptoms: psychiatric symptoms and clinical characteristics will be assessed using standardized instruments, including the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS), Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Hamilton Depression Rating Scale (HAMD), and Hamilton Anxiety Rating Scale (HAMA).
  2. Psychosocial functioning: functional outcomes will be evaluated using the Personal and Social Performance Scale (PSP), Global Functioning: Social (GF: Social), Global Functioning: Role (GF: Role), and Global Assessment of Functioning (GAF).
  3. Neurocognitive functioning: cognitive performance will be assessed using the MATRICS Consensus Cognitive Battery (MCCB), covering domains such as attention, working memory, verbal learning, visual learning, reasoning, and social cognition.
  4. Natural language and speech analysis: natural language samples will be collected through open-ended interviews to characterize linguistic content, semantic coherence, syntactic organization, and acoustic features. These measures will be investigated as potential markers of psychosis risk and clinical outcomes.
  5. Eye-tracking assessments: eye-tracking techniques will be used to evaluate oculomotor behavior and visual attention processes. Eye movement parameters obtained from standardized assessment tasks will be investigated as potential behavioral markers associated with psychosis risk.
  6. Retinal imaging: noninvasive retinal imaging will be performed to assess retinal structural and vascular characteristics, as applicable. Retinal imaging measures will be explored as potential biomarkers associated with clinical symptoms, neurobiological characteristics, and psychosis risk.
  7. Neuroimaging and neurophysiological measures: brain function and related neurobiological characteristics will be investigated using electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), and magnetic resonance imaging (MRI).
  8. Biological markers: Biological samples will be collected to investigate inflammatory and immune markers, neurotrophic factors, neuroendocrine markers, metabolomic profiles, genomic characteristics, and polygenic risk scores.
  9. Exploratory biomarker and risk prediction analyses: exploratory analyses will be conducted to identify potential clinical, cognitive, neurophysiological, neuroimaging, ophthalmic, linguistic, and molecular biomarkers associated with transition to psychosis. Candidate predictors will include measures derived from electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), magnetic resonance imaging (MRI), eye-tracking, retinal imaging, natural language and speech analysis, and biological assessments, including inflammatory, neuroendocrine, metabolic, and genetic markers. Associations between candidate predictors and subsequent transition to psychosis will be investigated. Multivariable prediction models will be developed to evaluate whether the integration of multimodal biomarkers improves the prediction of psychosis transition beyond conventional clinical and demographic predictors.

Tipo di studio

Osservativo

Iscrizione (Stimato)

750

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200030
        • Reclutamento
        • Shanghai Mental Health Center
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 35 anni (Bambino, Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

This prospective observational cohort study will recruit individuals aged 12-35 years at clinical high risk for psychosis (CHR) and healthy controls. CHR participants will be recruited primarily from psychiatric clinical services at Shanghai Mental Health Center and screened using standardized clinical interviews. Healthy controls will be recruited from the community and screened to exclude psychosis-risk syndromes, psychiatric conditions specified in the eligibility criteria, and relevant family history of psychotic disorders.

Participants will be enrolled based on predefined eligibility criteria and informed consent. CHR participants will undergo longitudinal follow-up for up to 36 months, while healthy controls will undergo baseline and 2-month assessments.

Descrizione

Inclusion Criteria:

-

1. Clinical High Risk for Psychosis (CHR) group

  1. Aged 12-35 years, regardless of sex.
  2. Able to understand the study procedures and provide written informed consent. For participants younger than 18 years, written informed consent must also be obtained from a parent or legal guardian.
  3. Meets criteria for a clinical high-risk syndrome for psychosis, primarily characterized by the Attenuated Positive Symptom Syndrome (APSS), as assessed using SOPS. Attenuated positive symptoms must have reached the required severity and frequency thresholds within the preceding 12 months.

2. Healthy Control (HC) group

  1. Aged 12-35 years, regardless of sex.
  2. Able to understand the study procedures and provide written informed consent. For participants younger than 18 years, written informed consent must be obtained from a parent or legal guardian.

Exclusion Criteria:

-

1. CHR group

  1. Intellectual disability, defined as an intelligence quotient (IQ) below 70.
  2. Current or previous central nervous system disease. When necessary, the research team will determine the clinical relevance of a specific neurological condition.
  3. History of traumatic brain injury, with a score greater than 7 on the traumatic brain injury screening scale.
  4. History of a treated or untreated psychotic episode.

2. HC group

  1. Intellectual disability, defined as an intelligence quotient (IQ) below 70.
  2. Current or previous central nervous system disease. When necessary, the research team will determine the clinical relevance of a specific neurological condition.
  3. History of traumatic brain injury, with a score greater than 7 on the traumatic brain injury screening scale.
  4. Meeting criteria for any psychosis-risk syndrome, having a current or past psychotic disorder, or meeting diagnostic criteria for a personality disorder.
  5. Current use of psychotropic medication for treatment of any condition.
  6. A family history of a psychotic spectrum disorder in a first-degree relative.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
CHR group

Individuals identified as being at clinical high risk for psychosis based on the Structured Interview for Prodromal Syndromes (SIPS). Participants will undergo comprehensive clinical, cognitive, behavioral, neuroimaging, neurophysiological, ophthalmic, and biological assessments, as applicable. Longitudinal follow-up assessments will be conducted at 2, 6, 12, 24, and 36 months to monitor clinical outcomes, including transition to psychosis.

HC group

Healthy individuals will serve as a comparison group. Participants will undergo standardized clinical, cognitive, behavioral, neuroimaging, neurophysiological, ophthalmic, and biological assessments, as applicable. Assessments will be conducted at baseline and at 2 months to provide reference data for comparison with individuals at clinical high risk for psychosis.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Transition to psychosis within 36 months
Lasso di tempo: Baseline to 36 months

The primary outcome is the occurrence of transition to psychosis among CHR individuals during the 36-month follow-up period. Transition to psychosis will be determined according to the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS) criteria by trained clinical evaluators. The outcome will be recorded as whether psychosis transition occurred during follow-up.

Baseline to 36 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in attenuated psychotic symptom severity
Lasso di tempo: Baseline and months 2, 6, 12, 24, and 36

Attenuated psychotic symptoms will be assessed using SOPS, administered as part of SIPS. The severity of positive symptoms will be evaluated using the SOPS positive symptom subscale (P1-P5), with each item rated from 0 to 6 and a total score ranging from 0 to 30. Higher scores indicate greater symptom severity. Changes from baseline will be evaluated during follow-up.

Baseline and months 2, 6, 12, 24, and 36
Change in personal and social functioning
Lasso di tempo: Baseline and months 2, 6, 12, 24, and 36

Personal and social functioning will be assessed using the Personal and Social Performance Scale (PSP). The PSP provides a global score ranging from 1 to 100, with higher scores indicating better functioning. Changes in PSP total scores from baseline will be evaluated during follow-up.

Baseline and months 2, 6, 12, 24, and 36
Change in neurocognitive performance
Lasso di tempo: Baseline and month 2

Neurocognitive performance will be assessed using the MATRICS Consensus Cognitive Battery (MCCB). The battery evaluates seven cognitive domains: processing speed, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Standardized T-scores will be used to assess cognitive performance, with higher scores indicating better functioning. Changes in cognitive performance from baseline will be evaluated.

Baseline and month 2

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Jijun Wang, Shanghai Mental Health Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 agosto 2026

Completamento primario (Stimato)

30 dicembre 2033

Completamento dello studio (Stimato)

30 dicembre 2033

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2025-SFDL05

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data, including selected clinical, cognitive, neuroimaging, neurophysiological, ophthalmic, linguistic, and biological measures, may be shared with qualified researchers for approved scientific purposes upon reasonable request. Data sharing will be subject to institutional approval, applicable ethics requirements, and execution of appropriate data use agreements. Only the minimum necessary data will be provided through secure, controlled-access mechanisms. Sensitive data, including individual-level genetic information and raw neuroimaging data, will be subject to additional restrictions. Cross-border data transfers will not be permitted without all required regulatory approvals.

Periodo di condivisione IPD

Selected de-identified individual participant data may be made available after completion of relevant analyses, subject to data availability and institutional approval. Access will be granted for a defined period specified in the data use agreement, with renewal subject to further approval.

Criteri di accesso alla condivisione IPD

Access to de-identified individual participant data will be considered for qualified researchers with scientifically justified proposals. Requests must be reviewed and approved by the principal investigator and the responsible institution, with ethics approval obtained when required. Approved researchers must sign a data use agreement specifying the permitted research purposes, data scope, access duration, confidentiality obligations, and restrictions on re-identification and onward sharing. Only the minimum necessary data will be provided through secure, encrypted transfer. Access to sensitive genetic, neuroimaging, and other regulated data will be subject to additional restrictions. Cross-border data sharing will require all applicable institutional and regulatory approvals.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .